Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval
IvelinRadkov Sanofi (NASDAQ:SNY) and Regeneron Pharmaeuticals (NASDAQ:REGN) Dupixent (dupiliumab), already a blockbuster drug approved for several indications, including asthma and eosinophilic esophagitis, is poised for further gains…
